CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke.
Return on Assets (ROA): CG Oncology's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.12%, the company may face hurdles in generating ...
7don MSN
HC Wainwright raises its price target on CG Oncology, Inc. (CGON) to $80 and maintains a buy rating
CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, H.C. Wainwright raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 ...
In a move that will be seized on as a sign that the IPO window is reopening in 2023, CG Oncology has not only become the first biotech to go public this year but overshot its own estimates. The ...
Communications firm CG Life rolled out a brand refresh Wednesday morning to highlight its commitment to science. The Shaped by Science rebrand seeks to underscore the inspiration behind the agency’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results